Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Financial Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

Genomics has published groundbreaking research revealing that 8% of the UK's adult population carries a polygenic risk for heart disease equivalent to that of carriers of Familial Hypercholesterolemia (FH). This polygenic group, previously undetected by the NHS, accounts for a significant portion of early heart disease cases—18 times more than those caused by FH.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Financial Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

Genomics has published groundbreaking research revealing that 8% of the UK's adult population carries a polygenic risk for heart disease equivalent to that of carriers of Familial Hypercholesterolemia (FH). This polygenic group, previously undetected by the NHS, accounts for a significant portion of early heart disease cases—18 times more than those caused by FH.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Financial Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

Genomics has published groundbreaking research revealing that 8% of the UK's adult population carries a polygenic risk for heart disease equivalent to that of carriers of Familial Hypercholesterolemia (FH). This polygenic group, previously undetected by the NHS, accounts for a significant portion of early heart disease cases—18 times more than those caused by FH.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer